---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-112839"
form_type: "8-K"
ticker: null
cik: "0001652724"
company_name: "Lucira Health, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:00:42.119163+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lucira Health sells substantially all assets to Pfizer for ~$36.4M in bankruptcy

## Summary
- Asset sale closed April 20, 2023, after Chapter 11 court approval on April 19.
- Total consideration ~$36.4M: $5M cash, cure costs, plus additional payments up to $10.4M.
- Amendment increased base consideration by $10.4M and fixed Jabil cure costs at $6.5M.
- Company had $132.8M federal and $81.6M state NOLs as of April 1, 2023.
- Pfizer won Section 363 auction on April 6, 2023; sale includes substantially all assets.

## SEC filing metadata
- accession: 0001193125-23-112839
- form_type: 8-K
- cik: 0001652724
- company_name: Lucira Health, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652724/000119312523112839/0001193125-23-112839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652724/000119312523112839/d446319d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-112839
- JSON: https://secwatch.observer/filing/0001193125-23-112839.json
- Plain text: https://secwatch.observer/filing/0001193125-23-112839.txt

## Key facts
- M&A Transactions
  Lucira Health, Inc. completed a disposition involving Pfizer Inc. for approximately $36.4 million (closed 2023-04-20).
  - Action: disposition
  - Counterparty: Pfizer Inc.
  - Consideration: approximately $36.4 million
  - Closing: 2023-04-20
  source text: 19, 2023, the Bankruptcy Court entered an order approving the sale of substantially all of the Company’s assets to the Buyer pursuant to the Purchase Agreement for approximately $36.4 million, which is comprised of a combination of cash, payments of Cure Costs to counterparties to assigned contracts and leases, and assumed or otherwise satisfied liabilities (the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652724/000119312523112839/0001193125-23-112839-index.htm
- Material Agreements
  Lucira Health, Inc. amended Amendment to Asset Purchase Agreement with Pfizer Inc. (effective 2023-04-18).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Pfizer Inc.
  - Effective: 2023-04-18
  source text: On April 18, 2023, the Company entered into an Amendment to Asset Purchase Agreement (the “Amendment”) with the Buyer that amended the Asset Purchase Agreement by and between the Company and the Buyer, dated April 12, 2023 (the “Original Purchase Agreement,” and as amended by the Amendment, the “Purchase Agreement”). The Amendment amended the Original Purchase Agreement to, among other things, (i) update the consideration and payment section to specify a fixed dollar amount of $6.5 million for the aggregate amount to be paid to cure any defaults (the “Cure Costs”) under each of the Jabil Contracts (as defined in the Purchase Agreement) and (ii) add an additional cash payment of $10.4 million less the aggregate amount of Cure Costs paid, satisfied or resolved by the Buyer in connection with certain other contracts as described therein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652724/000119312523112839/0001193125-23-112839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.